We have previously demonstrated in patients dialyzed with cuprophane membranes an increased production of both interleukin 6 (IL-6) and Beta 2-microglobulin (β2-m) by cultured peripheral blood mononuclear cells (PBMC). No study has addressed this issue in patients undergoing CAPD, a treatment characterized by absence of blood interaction with bio(in)compatible membranes. To investigate the systemic inflammatory events secondary to CAPD, we evaluated the release of both IL-6 and β2-m by PBMC obtained from peritonitis-free CAPD patients. These measurements were compared with those obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (UR) and healthy control subjects (C). In CAPD, IL-6 production from PBMC was markedly increased with respect to the control value (600.7 ± 104.3 vs 14.2 ± 3.6 pg/3 x 106 PBMC/24 hr, respectively) but was similar to the value found in HD patients (664.4 ± 138.9 pg/3 x 106 PBMC/24 hr). Similarly a striking increase in β2-m PBMC release was detected in CAPD with respect to C (10.1 ± 1.6 vs 0.063 ± 0.013 μg/3 x 106 PBMC/24 hr, respectively). In conclusion, CAPD induces per se activation of PBMC with enhanced release of IL-6 and β2-m. These systemic inflammatory events, being comparable with those occurring in HD, indicate that CAPD may not be different from HD in terms of bioincompatibility.
|Translated title of the contribution||Bioincompatibility of peritoneal dialysis|
|Number of pages||6|
|Journal||Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia|
|Publication status||Published - 1996|
ASJC Scopus subject areas